Pramila Ramani
Overview
Explore the profile of Pramila Ramani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paul S, Raja D, Sandhu B, Rao S, Spray C, Wiskin A, et al.
Arch Dis Child
. 2022 Feb;
107(8):747-751.
PMID: 35172964
Objective: European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines on coeliac disease (CD) recommend that children who have IgA-based antitissue transglutaminase (TGA-IgA) titre ≥10× upper limit of normal...
2.
Paul S, Sandhu B, Spray C, Basude D, Ramani P
J Pediatr Gastroenterol Nutr
. 2017 Sep;
66(4):641-644.
PMID: 28957985
Objective: The European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines for diagnosing celiac disease (CD) in children were modified in 2012. They recommend that in symptomatic children with...
3.
Jones I, Ramani P, Spray C, Cusick E
J Pediatr Gastroenterol Nutr
. 2017 Jun;
66(1):69-72.
PMID: 28562521
Objectives: We reviewed all children who have undergone a colectomy for ulcerative colitis (UC) in our tertiary referral centre in a 12-year period to assess the rate of reclassification as...
4.
Ramani P, Nash R, Sowa-Avugrah E, Rogers C
J Neurooncol
. 2015 Aug;
125(1):103-11.
PMID: 26318737
Despite multimodality treatment, the long-term survival of high-risk patients with neuroblastomas is below 50%. New anti-mitotic drugs against targets, such as polo-like kinase 1 (PLK1), are being evaluated in early...
5.
Ramani P, Sowa-Avugrah E, May M
Virchows Arch
. 2015 Jul;
467(3):319-27.
PMID: 26199132
Expression profile analysis of cell cycle biomarkers provides a powerful index of the proliferative state of tumors, which is linked to disease aggressiveness. We investigated the impact of the biomarkers...
6.
Ramani P, Taylor S, Miller E, Sowa-Avugrah E, May M
J Histochem Cytochem
. 2015 Feb;
63(6):397-407.
PMID: 25711230
Phosphohistone H3 (pHH3), a biomarker of the late G2- and M-phase of the cell cycle, provides a powerful indication of the proliferative state of many cancers. We investigated the prognostic...
7.
Ramani P, Nash R, Rogers C
Histopathology
. 2014 Oct;
66(3):370-9.
PMID: 25297850
Aims: To compare the expression and prognostic value of the cell cycle markers Aurora kinase A (AURKA) and Ki67 in neuroblastoma, because AURKA expression levels have greater prognostic significance than...
8.
Ramani P, Headford A, Sowa-Avugrah E, Hunt L
Int J Exp Pathol
. 2013 Feb;
94(2):115-25.
PMID: 23419171
Angiogenin (ANG) is a potent angiogenic factor that is up-regulated by hypoxia. ANG expression is well documented in normal tissues and in common tumours, but its expression has not been...
9.
Ramani P, Headford A, May M
Virchows Arch
. 2013 Jan;
462(2):203-9.
PMID: 23307190
GLUT1 is a hypoxia-induced gene that has many biologically important functions, and the overexpression of the GLUT1 protein correlates with poor prognosis in several adult cancers. The clinical significance of...
10.
Bates D, Catalano P, Symonds K, Varey A, Ramani P, ODwyer P, et al.
Clin Cancer Res
. 2012 Oct;
18(22):6384-91.
PMID: 23104894
Purpose: Bevacizumab improves survival for patients with metastatic colorectal cancer with chemotherapy, but no proven predictive markers exist. The VEGF-A splice form, VEGF(165)b, anti-angiogenic in animal models, binds bevacizumab. We...